BlackRock and RA Capital Management led a $100m Series C round in TScan Therapeutics.

BlackRock and RA Capital Management, a multi-stage investment manager, led a $100m Series C round in TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor engineered T-cell therapies in oncology. Existing investors including founding investor Longwood Fund, 6 Dimensions Capital, Bessemer Venture Partners, GV, Novartis Venture Fund and Pitango HealthTech also participated in the round. “This funding will enable TScan to progress its first two TCR-T cell assets into the clinic in 2021, with three additional programs to enter the clinic in 2022. I’m excited to welcome this new syndicate of distinguished healthcare investors to TScan. Recently, we have identified over 40 novel cancer targets from clinically active TCRs for development of multiplexed TCR-T cell therapies as part of our solid tumor program. Our goal is to continue to build a bank of clinically-active TCRs throughout 2021 to help patients win their fight against cancer," David Southwell, TScan CEO.